Table 5. Univariate and Multivariate OR and 95% CI for Association of Postoperative Complications.
| Absence (n = 87) | Complicate (n = 34) | Univariate OR (95% CI) | P-value | Multivariate OR (95% CI)† | P-value | |
|---|---|---|---|---|---|---|
| Age (years) | ||||||
| < 75 | 58 | 20 | 1 | 1 | ||
| ≥ 75 | 29 | 14 | 1.40 (0.62 - 3.17) | 0.419 | 1.66 (0.67 - 4.13) | 0.274 |
| Sex | ||||||
| Female | 33 | 7 | 1 | 1 | ||
| Male | 54 | 27 | 2.36 (0.92 - 6.02) | 0.073 | 2.80 (1.01 - 7.79) | 0.049 |
| Stage | ||||||
| Stage I-II | 52 | 22 | 1 | |||
| Stage III | 33 | 11 | 0.79 (0.34 - 1.83) | 0.580 | ||
| Failure: 3 | ||||||
| Disease | ||||||
| Colorectal cancer | 59 | 23 | 1 | |||
| Stomach cancer | 28 | 11 | 1.01 (0.43 - 2.35) | 0.986 | ||
| Charlson comorbidity index (points) | ||||||
| ≤ 2 | 81 | 28 | 1 | |||
| > 3 | 6 | 6 | 2.89 (0.86 - 9.71) | 0.085 | ||
| Histological type | ||||||
| Undifferentiated | 9 | 2 | 1 | |||
| Differentiated | 78 | 32 | 1.85 (0.38 - 9.02) | 0.449 | ||
| CEA (ng/mL) | ||||||
| < 6 | 50 | 21 | 1 | |||
| ≥ 6 | 35 | 11 | 0.75 (0.32 - 1.75) | 0.503 | ||
| Failure: 4 | ||||||
| CA19-9 (U/mL) | ||||||
| < 37 | 74 | 24 | 1 | 1 | ||
| ≥ 37 | 7 | 8 | 3.52 (1.16 - 10.74) | 0.027 | 3.95 (1.24 - 12.64) | 0.021 |
| Failure: 8 | ||||||
| CRP (mg/dL) | ||||||
| < 0.2 | 36 | 13 | 1 | |||
| ≥ 0.2 | 37 | 18 | 1.35 (0.58 - 3.15) | 0.491 | ||
| Failure: 17 | ||||||
| Albumin (g/dL) | ||||||
| ≥ 3.5 | 50 | 19 | 1 | |||
| < 3.5 | 25 | 11 | 1.16 (0.48 - 2.80) | 0.745 | ||
| Failure: 16 | ||||||
| Hemoglobin (g/dL) | ||||||
| ≥ male 11; female 10 | 57 | 20 | 1 | |||
| < male 11; female 10 | 20 | 10 | 1.43 (0.57 - 3.56) | 0.448 | ||
| Failure: 14 | ||||||
| HbA1c (%) | ||||||
| < 6.5 | 52 | 22 | 1 | |||
| ≥ 6.5 | 12 | 6 | 1.18 (0.39 - 3.55) | 0.766 | ||
| Failure: 29 | ||||||
| PNI (points) | ||||||
| ≥ 40 | 58 | 22 | 1 | |||
| < 40 | 13 | 7 | 1.42 (0.50 - 4.02) | 0.510 | ||
| Failure: 21 | ||||||
| BMI (kg/m2) | ||||||
| 18.5 - 24.9 | 59 | 22 | 1 | |||
| < 18.5 | 14 | 8 | 1.53 (0.57 - 4.15) | 0.401 | ||
| ≥ 25 | 14 | 4 | 0.77 (0.23 - 2.58) | 0.668 | ||
| P for trend 0.313 | ||||||
| SMI (kg/m2) | ||||||
| ≥ male 6.25; female 5.17 | 70 | 22 | 1 | |||
| < male 6.25; female 5.17 | 17 | 12 | 2.25 (0.93 - 5.42) | 0.072 | ||
| VFA (cm2) | ||||||
| ≥ 100 cm2 | 43 | 13 | 1 | |||
| < 100 cm2 | 42 | 18 | 1.42 (0.62 - 3.25) | 0.410 | ||
| Failure: 5 | ||||||
| Body fat (%) | ||||||
| ≥ male 30; female 42 | 9 | 5 | 1 | |||
| < male 30; female 42 | 78 | 29 | 0.67 (0.21 - 2.16) | 0.502 | ||
| Treatment technique | ||||||
| Laparoscopic | 17 | 5 | 1 | |||
| Laparotomy | 70 | 29 | 1.41 (0.48 - 4.18) | 0.537 | ||
| Chemotherapy | ||||||
| Absence | 55 | 22 | 1 | |||
| Prescription | 32 | 12 | 0.94 (0.41 - 2.14) | 0.879 |
PNI: prognostic nutritional index; CEA: carcinoembryonic antigen; CA19-9: carbohydrate antigen 19-9; CRP: C-reactive protein; VFA: visceral fat area; BMI: body mass index; SMI: skeletal muscle mass index. †Model included age, sex and CA19-9.